Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary
A

Alirocumab

Availability of ACE Drug Guidance

Yes

Biologics Drug Information Overview

Yes

Subsidy Information and Financing Scheme

No

Active ingredient: Alirocumab

General information

Subsidy Information and Financing Scheme

Not Applicable

Drug Guidance for Subsidy

02/01/2024 PCSK9 inhibitors for treating hypercholesterolaemia

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Evolocumab 140 mg/mL solution for injection in prefilled autoinjector for treating:

    • non-familial hypercholesterolaemia (non-FH) or mixed dyslipidaemia, with atherosclerotic cardiovascular disease (ASCVD) and additional risk factors and LDL-c level above 1.8 mmol/L despite maximal tolerated lipid-lowering therapy (LLT) for at least 12 weeks; or

    • heterozygous familial hypercholesterolaemia (HeFH), with ASCVD and LDL-c level above 1.8 mmol/L despite maximal tolerated LLT for at least 12 weeks; or

    • HeFH, without ASCVD, and LDL-c level above 2.6 mmol/L despite maximal tolerated LLT for at least 12 weeks; or

    • homozygous familial hypercholesterolaemia (HoFH) with LDL-c level above 1.8 mmol/L despite maximal tolerated statin-lowering therapy for at least 12 weeks.

Funding status

[R] Evolocumab 140 mg/mL solution for injection in prefilled autoinjector is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications from 1 November 2023.

[R] The dose of evolocumab for the treatment of non-FH or mixed dyslipidaemia and HeFH recommended for subsidy is 140 mg every 2 weeks. The dose restriction does not apply to HoFH.

[R] Evolocumab should be used in line with the additional clinical criteria listed in the Annex.

[NR] MAF assistance does not apply to any formulations or strengths of alirocumab or inclisiran for treating hypercholesterolaemia.

View legend

General Availability in Public Healthcare Institution

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Availability information

Formulation

Public Healthcare Institution

Praluent Injection, Solution (Prefilled Pen) 75 mg/mL

  1. Tan Tock Seng Hospital

Praluent Injection, Solution (Prefilled Pen) 150 mg/mL

  1. Tan Tock Seng Hospital

List of monographs containing this active ingredient

Alirocumab [Praluent]

Back to top